Kalli C. Catcott

Mersana Therapeutics (United States) — United States

Medicine · Health Sciences

11h-index376citations116works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(56), Monoclonal and Polyclonal Antibodies Research(55), Synthesis and Biological Evaluation(39), Radiopharmaceutical Chemistry and Applications(24), interferon and immune responses(22)

Publications116 total

Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
2025Open Access
Supplementary Figure S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S7 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Data from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S6 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S5 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S8 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Clinical Cancer Research·2025· 20 citedOpen Access
1053 XMT-2056, a HER2-targeted immunosynthen STING agonist antibody-drug conjugate, induces anti-tumor activity at low doses in preclinical models
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses
Nature Communications·2024· 55 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Timothy B. Lowinger(38), Marc Damelin(38), Dorin Toader(37), Scott D. Collins(29), Joshua D. Thomas(27), LiuLiang Qin(27), Ling Xu(26), Eugene Kelleher(25), Marina Protopopova(22), Elena Ter‐Ovanesyan(22), Brian Jones(21), Mao Yin(18), Rebecca Mosher(17), Aleksandr V. Yurkovetskiy(17), Natalya D. Bodyak(16), Shuyi Tang(16), Liping Yang(16), Daniel Custar(16), Damon R. Demady(16), Charlie Bu(16)